News brief­ing: Dew­point scores an­oth­er Big Phar­ma deal, this time with Pfiz­er; Kite joins forces with Ox­ford Bio­Ther­a­peu­tics

Over the last 13 months, Dew­point Ther­a­peu­tics has scored big part­ner­ships with Bay­er and Mer­ck, aim­ing to pi­o­neer a new field of bi­ol­o­gy called bio­mol­e­c­u­lar con­den­sates. On Wednes­day, the biotech reeled in an­oth­er big phar­ma deal.

Dew­point agreed to a re­search col­lab­o­ra­tion with Pfiz­er on Wednes­day for the de­vel­op­ment of ther­a­pies for my­oton­ic dy­s­tro­phy type 1, a rare ge­net­ic dis­or­der. The deal can be worth up to $239 mil­lion when ac­count­ing for all mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.